2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

مواد مشابهة

• 12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
  حسب: Kümmerle-Deschner J, وآخرون
  منشور في: (2008-09-01)
• Additional Benefit of Canakinumab on Proteinuria in a Case With Muckle-Wells Syndrome in Remission Under Anakinra
  حسب: Ufuk İLGEN, وآخرون
  منشور في: (2020-03-01)
• 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
  حسب: Ruperto N, وآخرون
  منشور في: (2008-09-01)
• Delayed diagnosis of Muckle-Wells syndrome – analysis of influencing factors
  حسب: Kuemmerle-Deschner Jasmin B, وآخرون
  منشور في: (2012-07-01)
• Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
  حسب: Angel Luis Salcedo-Mingoarranz, وآخرون
  منشور في: (2023-12-01)